Literature DB >> 9832641

Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan.

E Higashihara1, K Nutahara, M Kojima, A Tamakoshi, O Yoshiyuki, H Sakai, K Kurokawa.   

Abstract

UNLABELLED: The prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease (ADPKD) in Japan were estimated. Hospital-based nationwide surveys were conducted in 1995. The number of ADPKD patients who visited hospitals but were not on chronic dialysis was estimated to be 10,000 (95% confidence interval: 8, 200-11,900) and that of ADPKD patients on dialysis was 4,590, yielding a prevalence of ADPKD of 117 per million population at the end of 1994 (95% confidence interval: 102-132). The prevalence increased with age and reached a peak value of 261 per million population at the age group of 55-59 years. The rate of end-stage renal disease among living patients was calculated based on the assumption that the prevalence of ADPKD in the population under the age of 55 years was 261 per million population. The rate of end-stage renal disease increased with the progression of the patients' age, reaching 49% at the age of 65-69 years and declining thereafter.
CONCLUSION: The hospital-based prevalence of ADPKD is lower than the autopsy-based prevalence, suggesting that a fairly large number of these patients do not receive medical care in their lifetime. The probability of end-stage renal disease is at most 50% among ADPKD patients who visit a hospital.

Entities:  

Mesh:

Year:  1998        PMID: 9832641     DOI: 10.1159/000045214

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  34 in total

1.  The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial.

Authors:  Satoru Muto; Haruna Kawano; Eiji Higashihara; Ichiei Narita; Yoshifumi Ubara; Takayuki Matsuzaki; John Ouyang; Vicente E Torres; Shigeo Horie
Journal:  Clin Exp Nephrol       Date:  2015-02-07       Impact factor: 2.801

Review 2.  ADPKD: molecular characterization and quest for treatment.

Authors:  Shigeo Horie
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

3.  Acute pulmonary thromboembolism occurring during treatment with tolvaptan in a patient with autosomal-dominant polycystic kidney disease.

Authors:  Katsuhiko Morimoto; Yasuhiro Akai; Masaru Matsui; Hiroki Yano; Miho Tagawa; Ken-Ichi Samejima; Yoshihiko Saito
Journal:  CEN Case Rep       Date:  2017-01-24

4.  Bacteremic kidney cyst infection caused by Helicobacter cinaedi.

Authors:  Kenta Ito; Takumi Yamamoto; Haruomi Nishio; Asako Sawaya; Masaaki Murakami; Akiko Kitagawa; Yoko Matsuo; Ken Matsuo; Satoshi Tanaka; Noriko Mori
Journal:  CEN Case Rep       Date:  2015-12-10

5.  Angiotensinogen gene polymorphisms and progression of chronic kidney disease in ADPKD patients.

Authors:  Ramanathan Gnanasambandan; Ramprasad Elumalai; Periyasamy Soundararajan; Bhaskar V K S Lakkakula
Journal:  Clin Exp Nephrol       Date:  2015-10-19       Impact factor: 2.801

6.  Sleep-Disordered Breathing in Patients with Polycystic Liver and Kidney Disease Referred for Transcatheter Arterial Embolization.

Authors:  Keiichi Sumida; Junichi Hoshino; Tatsuya Suwabe; Takatoshi Kasai; Noriko Hayami; Koki Mise; Masahiro Kawada; Aya Imafuku; Rikako Hiramatsu; Eiko Hasegawa; Masayuki Yamanouchi; Naoki Sawa; Koji Narui; Kenmei Takaichi; Yoshifumi Ubara
Journal:  Clin J Am Soc Nephrol       Date:  2015-03-30       Impact factor: 8.237

7.  Prevalence of genetic renal disease in children.

Authors:  Jeffery Fletcher; Stephen McDonald; Stephen I Alexander
Journal:  Pediatr Nephrol       Date:  2012-09-29       Impact factor: 3.714

8.  Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.

Authors:  A Lianne Messchendorp; Esther Meijer; Folkert W Visser; Gerwin E Engels; Peter Kappert; Monique Losekoot; Dorien J M Peters; Ron T Gansevoort
Journal:  Am J Nephrol       Date:  2019-10-10       Impact factor: 3.754

9.  Kidney dysfunction following adrenalectomy in autosomal dominant polycystic kidney disease complicated with primary aldosteronism: A case report.

Authors:  Hiroyuki Hirai; Makoto Kanno; Tsuyoshi Watanabe; Hiroaki Satoh
Journal:  Exp Ther Med       Date:  2017-06-13       Impact factor: 2.447

10.  Survival after arterial embolization therapy in patients with polycystic kidney and liver disease.

Authors:  Junichi Hoshino; Tatsuya Suwabe; Noriko Hayami; Keiichi Sumida; Koki Mise; Masahiro Kawada; Aya Imafuku; Rikako Hiramatsu; Masayuki Yamanouchi; Eiko Hasegawa; Naoki Sawa; Ryoji Takei; Kenmei Takaichi; Yoshifumi Ubara
Journal:  J Nephrol       Date:  2014-09-18       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.